CancerOption.com Appoints Germany's Dr. Friedrich R. Douwes, M.D., Oncologist, to Its Scientific Advisory Board, Second Analyst Initiates Research Coverage.

SCOTTSDALE, Ariz--(BUSINESS WIRE)--Aug. 26, 1999--

(OTC Bulletin Board:CAOP) CancerOption.com, Inc. announced today the appointment of Dr. Friedrich R. Douwes, M.D., Medical Director, Professor of Internal Medicine and Oncology at Klinik St. Georg of Bad Aibling, Germany. Dr. Douwes founded Klinik St. Georg in 1991 and treats over 5,000 patients annually, integrating holistic and traditional treatments of cancer. Dr. Douwes is recognized as one of the world's experts on hyperthermia and electrolytic therapies for cancer. These therapies are unique, safe and effective methods that are part of the protocol therapies at Klinik St. Georg.

In addition to Klinik St. Georg, Dr. Douwes impressive Curriculum Vitae includes: Medical Director of Sonnenberg Clinic for Oncology, Bad Sooden-Allendorf, Germany; Chief Physician and Medical Director of VERAMED Cancer Hospitals, Brannenburg, Nussdorf, Mechede, Germany; Editor of the German Journal of Oncology. Dr. Douwes is presently the Vice President of the German Society of Oncology and has published over 100 scientific papers to date, specializing in alternative cancer treatments.

Arnold Takemoto, President and Chief Executive Officer of CancerOption.com, said, "Dr. Douwes appointment further exemplifies our commitment of establishing the most reputable doctor-based Scientific Advisory Board in the alternative healthcare field. His expertise in hyperthermia and ECT (Electro Cancer Therapies) along with traditional specialty training in cancer, will further educate our audience in research, content and cancer treatments." Mr. Takemoto further comments, "Along with current Scientific Advisory Board members, Dr. Privitera, Dr. Brenner and Director Dr. Brodie, the appointment of Dr. Douwes further diversifies the continuing development of our Scientific Advisory Board."

Second Analyst Initiates Coverage

Along with Dennis Hass of Stockreporter.de, a well-recognized European financial concern, Mr. Doug Wetzel of Gilbert & Chatteron initiates coverage on Canceroption.com with a strong buy recommendation and a short-term target price of $15.00 per share, 2-year target price of $30 per share. "We believe CancerOption.com is one of the most exciting Internet Companies to enter the new millennium. Not only is the Company a first mover, but the worldwide humanitarian effect that this portal will have is compelling. CancerOption.com offers integrative and complementary approaches as they relate to cancer. This rare component includes specific products and protocols that work in conjunction with traditional methods. In addition, the portal offers research and clinical studies, as well as access to the medical community and specialists around the world."

Mr. Wetzel continues "With the Company's unique business model and the millions of people that are relying on the Internet for healthcare information, our valuation may seem conservative, especially when you compare drkoop.com's (NASDAQ: KOOP) share price which went from a low of $10 to over $30 per share and Healtheon (NASDAQ: HLTH) which has a market cap over $2 billion." Mr. Wetzel concludes, "This Company is composing an elite Scientific Advisory Board that has an international appeal. These doctors, combined, have over 100 years experience in treating cancer patients through traditional, alternative and complementary methods, which can only advance the future success of CancerOption.com."

The Gilbert & Chatterton research report is available at www.canceroption.com/investor/gcreport.htm About CancerOption.com

CancerOption.com's mission is to provide a clear and concise informational stream of content in an effort to educate the general public and physicians on a variety of methods to enhance the immune system as it relates to cancer. Within the CancerOption.com virtual community, forums discussing the latest research findings, clinical trials, traditional and alternative therapies as well as professional forums with oncologists, physicians and healthcare professionals will be available worldwide. CancerOption.com's protocols and targeted nutraceuticals work in conjunction with current traditional cancer therapies. For additional information, visit us online at www.canceroption.com.

Disclaimer: This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.